Loading stock data…
Lucyd (LUCY)
$0.82+0.04 (+4.75%)
Market ClosedLast close Jun 29
Lucyd, Inc develops and sells smart eyewear in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lucyd, Inc in the Healthcare sector is trading at $0.82 with a market capitalization of $6M. The stock is currently near its 52-week low of $0.66, remaining 37.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $773,561↓ | $959,810↑ | $668,128↑ | $579,230↑ | $454,501 |
| Gross Profit | $175,445↑ | $114,746↓ | $244,837↑ | -$12,665↓ | $220,533 |
| Operating Income | -$2.37M↑ | -$2.50M↓ | -$1.92M↑ | -$2.17M↓ | -$1.90M |
| Net Income | -$2.31M↓ | -$1.87M↓ | -$1.84M↑ | -$2.11M↓ | -$1.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescript...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.04%
Volume
Today's trading volume
58,088
Recent News
Top Midday Gainers
Monte Rosa Therapeutics (GLUE) said Wednesday early trial results of its drug candidate, MRT-8102, s
BC-Most Active Stocks
HIVE Digital Technologies Ltd. 18,030,962 3.2599
Innovative Eyewear Second Quarter 2025 Earnings: US$0.66 loss per share (vs US$1.87 loss in 2Q 2024)
NasdaqCM:LUCY 1 Year Share Price vs Fair Value Explore Innovative Eyewear's Fair Values from the Community and select...